Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease NEW YORK and SALT LAKE CITY, Nov. 10, 2021 (GLOBE NEWSWIRE) -- In recognition of National Diabetes Month and concurrent with the launch of KidneyIntelX in the Veterans
Partnership expands doctor and patient access to advanced prognosis and coordinated care management of early-stage diabetic kidney disease NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- St. Joseph's Health and Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced a partnership to implement an
LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based
LONDON and SALT LAKE CITY, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results on Thursday, October 21, 2021, before market open.
Jed Fulk Appointed Vice President Sales, Government Accounts NEW YORK and SALT LAKE CITY, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the expansion of its commercial strategy to address early-stage kidney disease in the Veterans Health Administration
Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021 NEW YORK and SALT LAKE CITY, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) and the Mount Sinai Health System today announced scaled-up implementation of the KidneyIntelX™
NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference. Renalytix’s management is scheduled to participate
Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic NEW YORK and SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Daniel J.
Peer reviewed publication in Journal of Medical Economics supports payer coverage for early-stage risk assessment and care management in the primary care office NEW YORK and SALT LAKE CITY, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the publication of
Berman serves on the board of Loews Corporation, is a member of the board of trustees of Beth Israel Deaconess, and is a former chief financial officer of Harvard University NEW YORK and SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the
